News

ascopubs.org2d
Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC ... - ASCO Publications
Background: Ipilimumab and nivolumab (IPI-NIVO) and IO/vascular endothelial growth factor (VEGF) inhibitor combinations (IOVE) are now standard of care 1L treatment options for mRCC. However, there is ...
How-To Geek on MSN4d
I Love Using Excel Tables, but I Wish Microsoft Fixed One Major Problem
One way to get around this issue is to convert the Excel table to a range by selecting any cell in the table, and clicking ...